Compare Global X Robo Global Robotics & Automation ETF (ROBO) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Robo Global Robotics & Automation ETF vs TG Therapeutics Inc — how do they compare? Global X Robo Global Robotics & Automation ETF trades at $78.84, while TG Therapeutics Inc trades at $54.77 (market cap $8.36B). The key difference: TG Therapeutics Inc is trading nearer its 52-week high, Global X Robo Global Robotics & Automation ETF nearer its low. Which is the better fit depends on your goals.
| ROBO | TGTX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $90.34 | $59.06 |
52-Week Low | $63.04 | $26.94 |
Market Cap | — | $8.36B |
Enterprise Value | — | $8.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ROBO Global Robotics and Automation Index ETF (ROBO) trades at $79.65, down 1.14% with a bearish technical signal. The robotics ETF faces mixed momentum as moving averages indicate selling pressure while oscillators remain neutral. Recent news highlights accelerating robotics adoption across manufacturing, healthcare, and military applications, with NVIDIA's AI growth outlook providing sector tailwinds.
The ETF offers diversified exposure to robotics growth themes, though valuation metrics are unavailable. Key risks include sector concentration and AI adoption pace variability. Analyst sentiment appears cautiously optimistic given the structural growth drivers in industrial automation and physical AI applications.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
